| Combination Chemotherapy with Mitomycin C, Vinorelbine, and Cisplatin (MVrP) in Patients with Advanced Non-Small Cell Lung Cancer |
| Hun Gu Kim, Gyeong Won Lee, Dae Hwan Lee, In Gyu Hwang, Ki Shik Shim, Won Sup Lee, Jong Deog Lee, Joung Soon Jang, Young Sil Hwang, Jong Seok Lee |
| Department of Internal Medicine, College of Medicine,Gyeongsang National University, Jinju, Korea.jonglee@nongae.gsnu.ac.kr
|
|
Published online: October 31, 2001. |
|
|
|
| ABSTRACT |
PURPOSE:
A phase II study was conducted in patients with advanced non-small cell lung cancer (NSCLC) in order to evaluate the efficacy and toxicity of the combination chemotherapy regimen of mitomycin C, vinorelbine, and cisplatin (MVrP).
MATERIALS AND METHODS:
Between June 1996 and December 2000, fifty-nine patients with unresectable stage IIIB to IV, pathologically documented NSCLC were enrolled in this study.
One cycle consisted of mitomycin C 10 mg/m2 i.v. day 1, vinorelbine 30 mg/m2 i.v. days 1 & 15, and cisplatin 80 mg/m2 i.v day 1 and the next cycle consisted of vinorelbine 30 mg/m2 i.v. days 29 & 43, and cisplatin 80 mg/m2 i.v day 29. Each cycle was alternated and treatments were repeated every 8 weeks.
RESULTS:
We were able to evaluate fifty-three of 59 patients. Objective responses were seen in 22 (41.5%) patients (CR 0%, PR 41.5%). The median duration of response was 13.7 weeks and the median time to progression was 17.7 weeks. The median overall survival was 45.6 weeks. There was a significantly longer survival seen in responders (p=0.041). The toxicities of this regimen were acceptable without treatment related toxic death.
CONCLUSION:
This study suggests that a combination regimen of mitomycin C, vinorelbine, and cisplatin is relatively effective and well tolerated for the treatment of advanced NSCLC. |
| Key words:
Non-small cell lung cancer;Combination chemotherapy;Mitomycin C;Vinorelbine;Cisplatin |
|
PDF Links
Full text via DOI
Download Citation 
